Search results
Showing 301 to 315 of 496 results for anxiety
This quality standard covers diagnosing and managing renal cell carcinoma in adults (aged 18 and over). It describes high-quality care in priority areas for improvement.
View quality statements for QS215Show all sections
Sections for QS215
- Quality statements
- Quality statement 1: Suspected cancer pathway referral
- Quality statement 2: Renal biopsy for small renal lesions
- Quality statement 3: Clinical nurse specialist
- Quality statement 4: Surgery with curative intent
- Quality statement 5: Follow-up imaging
- Quality statement 6: Uro–oncology multidisciplinary team
- About this quality standard
This quality standard covers diagnosing, managing and treating rare diseases in children, young people and adults. It describes high-quality care in priority areas for improvement.
View quality statements for QS214Show all sections
Sections for QS214
- Quality statements
- Quality statement 1: Referral for investigation and treatment
- Quality statement 2: Undiagnosed conditions
- Quality statement 3: Information provision
- Quality statement 4: Shared decision making
- Quality statement 5: Named healthcare professional
- Quality statement 6: Holistic needs assessment
- Quality statement 7: Access to treatment
and communication needs , including the opportunity to discuss fears and anxieties. Relevant resources Guidelines Learning disabilities...
Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over (TA986)
Evidence-based recommendations on lebrikizumab (Ebglyss) for treating moderate to severe atopic dermatitis in people 12 years and over.
Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma (TA720)
Evidence-based recommendations on chlormethine gel (Ledaga) for treating early-stage mycosis fungoides-type cutaneous T-cell lymphoma in adults.
Romiplostim for the treatment of chronic immune thrombocytopenia (TA221)
Evidence-based recommendations on romiplostim (Nplate) for treating chronic immune thrombocytopenia in adults.
Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine (TA440)
Evidence-based recommendations on pegylated liposomal irinotecan (Onivyde) for treating pancreatic cancer in adults.
Botulinum toxin type A for the prevention of headaches in adults with chronic migraine (TA260)
Evidence-based recommendations on botulinum toxin type A (Botox) for preventing headaches in adults with chronic migraine.
The OraQuick HCV point‑of‑care test for rapid detection of hepatitis C virus antibodies (MIB24)
NICE has developed a medtech innovation briefing (MIB) on the OraQuick HCV point-of-care test for rapid detection of hepatitis C virus antibodies
This quality standard covers the clinical assessment and management of depression in adults aged 18 and over. It describes high-quality care in priority areas for improvement.
View quality statements for QS8Show all sections
Sections for QS8
- Quality statements
- Quality statement 1: Assessment
- Quality statement 2: Discussing treatment options
- Quality statement 3: Preventing relapse
- Quality statement 4: Stopping antidepressants
- Quality statement 5: Access to services for adults from minority ethnic backgrounds
- Update information
- About this quality standard
Service user experience in adult mental health services (QS14)
This quality standard covers improving the experience of people using adult NHS mental health services. It describes high-quality care in priority areas for improvement.
View quality statements for QS14Show all sections
Sections for QS14
- Quality statements
- Quality statement 1: Empathy, dignity and respect
- Quality statement 2: Decision making
- Quality statement 3: Involvement to improve services
- Quality statement 4: Contacts for ongoing care
- Quality statement 5: Access to services
- Quality statement 6: Joint care planning
- Quality statement 7: Inpatient contact with staff
Evidence-based recommendations on lusutrombopag (Mulpleo) for treating severe thrombocytopenia in adults with chronic liver disease needing a planned invasive procedure.
Dupilumab for treating moderate to severe atopic dermatitis (TA534)
Evidence-based recommendations on dupilumab (Dupixent) for treating moderate to severe atopic dermatitis in adults.
Evidence-based recommendations on ixazomib with lenalidomide and dexamethasone for relapsed or refractory multiple myeloma.
Brodalumab for treating moderate to severe plaque psoriasis (TA511)
Evidence-based recommendations on brodalumab (Kyntheum) for treating moderate to severe plaque psoriasis in adults.